7:42 PM
 | 
Mar 08, 2018
 |  BioCentury  |  Emerging Company Profile

Reviving lixivaptan

How Palladio plans to repurpose lixivaptan for ADPKD

Single-asset play Palladio Biosciences Inc. is repurposing lixivaptan as a safer alternative to Jinarc tolvaptan, a competing vasopressin 2 (V2) receptor antagonist associated with hepatotoxicity in patients with autosomal dominant polycystic kidney disease.

ADPKD is characterized by cyst formation and kidney enlargement, which can eventually lead to kidney failure. According to the company, about half of ADPKD patients require dialysis or kidney transplantation by age 60.

There are no disease-modifying therapies approved for ADPKD in the U.S., where, according to Palladio CEO Lorenzo Pellegrini, patients are treated for symptoms including pain and high blood pressure as the disease progresses.

Otsuka Pharmaceutical Co. Ltd. markets Jinarc for ADPKD in Europe, Canada and Japan, where Jinarc is the only approved therapy for slowing disease progression. However, patients in Europe and Canada are required to clear monthly liver screenings to stay on treatment and mitigate the risk of liver injury.

Pellegrini told BioCentury the safety...

Read the full 740 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >